What question did this study set out to answer?

This research aims to evaluate the efficacy of a non-blood liquid biopsy in identifying tumor-derived copy number variations (CNVs) for breast cancer detection and risk assessment.

May 24, 2026ESMO Open0 citationsOpen Access

383P Non-blood liquid biopsy in nipple discharge to decode tumor-derived CNV signatures for breast cancer detection and prognostication

PPP. Pu HXH. Xu YLY M Li

Key Points

This research aims to evaluate the efficacy of a non-blood liquid biopsy in identifying tumor-derived copy number variations (CNVs) for breast cancer detection and risk assessment.
Conducted a non-blood liquid biopsy analysis on nipple discharge samples.
Focused on carriers of pathogenic variants (M-PV) and BRCA2 genes.
Employed probabilistic genetic stratification (PGS) in risk estimation.
The addition of PGS significantly enhanced risk stratification for breast cancer.
Particularly notable improvements were observed in carriers of M-PV and BRCA2 genes.
Findings suggest potential for better-informed decision-making in clinical contexts.

Abstract

Conclusions: Adding PGS to BC risk estimation significantly modifies risk stratification, particularly in carriers of M-PV and in BRCA2 genes, which may provide valuable information for informed decision-making.

Ask AI

Helpful

Bookmark

View Full Paper